BACKGROUND: The determination of in situ protein levels of ERCC1 with the 8F1 monoclonal antibody is prognostic of survival in patients with non-small cell lung cancer (NSCLC). The authors previously demonstrated that 8F1 recognizes a second nuclear antigen. This antigen was identified and its value as a biomarker of clinical outcomes analyzed. METHODS: The second antigen was identified by mass spectrometry. Protein identity and antibody specificity were confirmed through knockdown and overexpression experiments. Immunohistochemistry of 187 early-stage NSCLC samples and 60 head and neck squamous cell carcinomas (HNSCCs) was used to examine the influence of the second antigen on 8F1 immunoreactivity and its association with patient outcomes. RESULTS: Choline phosphate cytidylyltransferase-α (CCTα, also known as phosphate cytidylyltransferase 1 choline alpha [PCYT1A], a phospholipid synthesis enzyme regulated by RAS) is the second antigen recognized by 8F1. In NSCLC samples, CCTα contributed (rho, 0.38) to 8F1 immunoreactivity. In samples of squamous cell carcinomas of the lung, CCTα was found to be the dominant determinant of 8F1 immunoreactivity, whereas its contribution in other subtypes of lung cancer was negligible. High expression of CCTα, but not ERCC1, was found to be prognostic of longer disease-free survival (log-rank P = .002) and overall survival (log-rank P = .056). Similarly, in patients with HNSCC, CCTα contributed strongly to 8F1 immunoreactivity (rho, 0.74), and high CCTα expression was found to be prognostic of survival (log-rank P = .022 for disease-free survival and P = .027 for overall survival). CONCLUSIONS: CCTα is the second antigen detected by 8F1. High CCTα expression appears to be prognostic of survival in patients with NSCLC who are treated by surgery alone and patients with HNSCC. CCTα is a promising biomarker of patient survival and deserves further study.
BACKGROUND: The determination of in situ protein levels of ERCC1 with the 8F1 monoclonal antibody is prognostic of survival in patients with non-small cell lung cancer (NSCLC). The authors previously demonstrated that 8F1 recognizes a second nuclear antigen. This antigen was identified and its value as a biomarker of clinical outcomes analyzed. METHODS: The second antigen was identified by mass spectrometry. Protein identity and antibody specificity were confirmed through knockdown and overexpression experiments. Immunohistochemistry of 187 early-stage NSCLC samples and 60 head and neck squamous cell carcinomas (HNSCCs) was used to examine the influence of the second antigen on 8F1 immunoreactivity and its association with patient outcomes. RESULTS:Choline phosphate cytidylyltransferase-α (CCTα, also known as phosphate cytidylyltransferase 1 choline alpha [PCYT1A], a phospholipid synthesis enzyme regulated by RAS) is the second antigen recognized by 8F1. In NSCLC samples, CCTα contributed (rho, 0.38) to 8F1 immunoreactivity. In samples of squamous cell carcinomas of the lung, CCTα was found to be the dominant determinant of 8F1 immunoreactivity, whereas its contribution in other subtypes of lung cancer was negligible. High expression of CCTα, but not ERCC1, was found to be prognostic of longer disease-free survival (log-rank P = .002) and overall survival (log-rank P = .056). Similarly, in patients with HNSCC, CCTα contributed strongly to 8F1 immunoreactivity (rho, 0.74), and high CCTα expression was found to be prognostic of survival (log-rank P = .022 for disease-free survival and P = .027 for overall survival). CONCLUSIONS: CCTα is the second antigen detected by 8F1. High CCTα expression appears to be prognostic of survival in patients with NSCLC who are treated by surgery alone and patients with HNSCC. CCTα is a promising biomarker of patient survival and deserves further study.
Authors: Alec Vaezi; Xiaozhe Wang; Shama Buch; William Gooding; Lin Wang; Raja R Seethala; David T Weaver; Alan D D'Andrea; Athanassios Argiris; Marjorie Romkes; Laura J Niedernhofer; Jennifer R Grandis Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: W E Pierceall; K A Olaussen; V Rousseau; E Brambilla; K M Sprott; F Andre; J-P Pignon; T Le Chevalier; R Pirker; C Jiang; M Filipits; Y Chen; J L Kutok; D T Weaver; B E Ward; J-C Soria Journal: Ann Oncol Date: 2012-01-23 Impact factor: 32.976
Authors: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: Nikhil R Bhagwat; Vera Y Roginskaya; Marie B Acquafondata; Rajiv Dhir; Richard D Wood; Laura J Niedernhofer Journal: Cancer Res Date: 2009-09-01 Impact factor: 12.701
Authors: Nileena Velappan; Devin Close; Li-Wei Hung; Leslie Naranjo; Colin Hemez; Natasha DeVore; Donna K McCullough; Antonietta M Lillo; Geoffrey S Waldo; Andrew R M Bradbury Journal: Protein Eng Des Sel Date: 2021-02-15 Impact factor: 1.650
Authors: Gerold Bepler; Ralph G Zinner; James Moon; Royce Calhoun; Kemp Kernstine; Charles C Williams; Philip C Mack; Vasco Oliveira; Zhong Zheng; Philip J Stella; Mary W Redman; David R Gandara Journal: Cancer Date: 2014-04-18 Impact factor: 6.860
Authors: Andrew R M Bradbury; Nathan D Trinklein; Holger Thie; Ian C Wilkinson; Atul K Tandon; Stephen Anderson; Catherine L Bladen; Brittany Jones; Shelley Force Aldred; Marco Bestagno; Oscar Burrone; Jennifer Maynard; Fortunato Ferrara; James S Trimmer; Janina Görnemann; Jacob Glanville; Philipp Wolf; Andre Frenzel; Julin Wong; Xin Yu Koh; Hui-Yan Eng; David Lane; Marie-Paule Lefranc; Mike Clark; Stefan Dübel Journal: MAbs Date: 2018-03-29 Impact factor: 5.857
Authors: Jan L A Voskuil; Anita Bandrowski; C Glenn Begley; Andrew R M Bradbury; Andrew D Chalmers; Aldrin V Gomes; Travis Hardcastle; Fridtjof Lund-Johansen; Andreas Plückthun; Giovanna Roncador; Alejandra Solache; Michael J Taussig; James S Trimmer; Cecilia Williams; Simon L Goodman Journal: MAbs Date: 2020 Jan-Dec Impact factor: 5.857